DGAP-News: Lindis Blood Care successfully closes follow-on financing round
Retrieved on:
Wednesday, February 9, 2022
Trial of the century, LANXESS, QIAGEN, Cancer, Safety, Collection, TAG Tegernsee Immobilien und Beteiligung, Federal Ministry of Health (Germany), Chemistry, Schwarz Gruppe, Oncology, Federal Ministry for Economic Affairs and Energy, SAP, Blood transfusion, Recurrence, FDA, Blood, Wilh. Wilhelmsen, European, Life expectancy, Metastasis, EUR, Certification, LBC, New Senior Investment Group, Regional development, Risk, Technology, Schufa, Investitionsbank Berlin, Committee on European Affairs and Oversight of the European Funds, Neoplasm, ILB, Vector Informatik, Economy, Deutsche Bank, Business Growth Fund, Boehringer Ingelheim, EWE, Deutsche Post, BASF, MAT, CE, Gold standard, IBS, Partnership, Medical device, Medical imaging, Fine chemical, Economics, PHOENIX, Lindis Blood Care, Brandenburg Kapital GMBH / ILB, LINDIS BLOOD CARE, BRANDENBURG KAPITAL GMBH / ILB
"This investment comes at an exciting time for Lindis Blood Care, and we are grateful for the continued support and trust that our investors have placed in our innovative approach," commented Dr. Franzpeter Bracht, founder and Managing Director of Lindis Blood Care.
Key Points:
- "This investment comes at an exciting time for Lindis Blood Care, and we are grateful for the continued support and trust that our investors have placed in our innovative approach," commented Dr. Franzpeter Bracht, founder and Managing Director of Lindis Blood Care.
- With its medical device CATUVAB(R), Lindis Blood Care aims to set a new Gold Standard in cancer patient blood management by reliably removing tumor cells from patient blood collected during surgery.
- Lindis Blood Care is a medical technology company developing the medical device CATUVAB(R).
- To date, external investors have injected more than EUR 4 billion into the HTGF portfolio via more than 1,800 follow-on financing rounds.